AI agents are coming to pharma. Here’s what it means for clinical trials.

The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

By Kelly Bilodeau • Sept. 17, 2025

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

By Alexandra Pecci • Sept. 16, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

By Kelly Bilodeau • Sept. 15, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 10, 2025

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.

By Alexandra Pecci • Sept. 10, 2025

At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.

By Delilah Alvarado , Jonathan Gardner • Sept. 5, 2025

Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats

With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.

By Michael Gibney • Sept. 3, 2025

How AI advances will shape the drugmaker of the future

An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

By Michael Gibney • Sept. 2, 2025

FDA approves updated COVID boosters, but narrows use

In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.

By Delilah Alvarado • Updated Aug. 27, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

AbbVie dives back into the neuro pool with a $1.2B psychedelics play

Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

By Michael Gibney • Aug. 26, 2025

FDA’s new accelerated pathway could open pharma up to risks, as well as benefits

Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.

By Amy Baxter • Aug. 25, 2025

And just like that... pharma’s breakups reveal pain points in cancer R&D

Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.

By Meagan Parrish • Aug. 22, 2025

The biggest Big Pharma losers in the first half of 2025

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

By Michael Gibney • Aug. 21, 2025

MAHA leaders may take aim at pharma DTC advertising

RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.

By Amy Baxter • Aug. 20, 2025

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.

By Kelly Bilodeau • Aug. 18, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

With scrapped mRNA funding, a vaccine maker finds a silver lining

While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

By Michael Gibney • Aug. 14, 2025

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

By Amy Baxter • Aug. 13, 2025

3 ways the GLP-1 market has changed shape this year

Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.

By Amy Baxter • Aug. 12, 2025

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

By Michael Gibney • Aug. 12, 2025

Are stem cell therapies ready for pharma’s prime time?

Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

By Kelly Bilodeau • Aug. 11, 2025